Objective. Adult-onset IgA vasculitis (HenochSch€ onlein) (IgAV) is a rare systemic vasculitis characterized by IgA1-dominant deposits. The treatment of adult-onset IgAV is controversial and is based on the combination of glucocorticoids and immunosuppressive agents, but many patients have refractory or relapsing disease despite treatment. Rituximab (RTX) is a B celldepleting antibody of proven efficacy in antineutrophil cytoplasmic antibody-associated vasculitis. We undertook this study to test the efficacy and safety of RTX in a multicenter cohort of patients with adult-onset IgAV.
IgA vasculitis (Henoch-Sch€ onlein) (IgAV) is a systemic small-vessel vasculitis characterized by IgA1-dominant immune deposits. Clinical manifestations include purpura, gastrointestinal involvement, arthritis, and glomerulonephritis (1) . IgAV is the most common vasculitis in children, while it is rare in adults. Childhood-onset IgAV usually has a benign course that only requires supportive care. In adults, its prognosis is worse, particularly because of the frequency and severity of renal involvement; indeed, adult-onset IgAV leads to advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) in 10-30% of patients with renal involvement (2) .
The treatment of adult-onset IgAV is still a matter of debate. Glucocorticoids and immunosuppressive drugs are routinely used, especially in patients with organ-or life-threatening manifestations (3) . However, the efficacy of these treatments is controversial. In the only randomized trial performed in adult-onset IgAV, the addition of cyclophosphamide to glucocorticoids failed to provide any clear benefit (4) . The efficacy of other immunosuppressive agents such as azathioprine, mycophenolate mofetil, or cyclosporine has only been reported in anecdotal cases (3, 5) . Therefore, effective therapies are needed in adult-onset IgAV.
The anti-CD20 monoclonal antibody rituximab (RTX) has become a standard treatment for remission induction and remission maintenance in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (6, 7) . RTX induces B cell depletion and thus dampens the expansion of plasma cells that produce pathogenic autoantibodies. RTX can also impair antigen presentation by B cells or reduce B cell-mediated stimulation of T cells and other inflammatory cell types (6) . Recent studies have shown that RTX may be effective for adult-onset IgAV, but they were based on single cases or small case series (8, 9) . In this multicenter observational study, we analyzed the effectiveness and safety of RTX in patients with adult-onset IgAV who either had relapsing or refractory disease or had contraindications to conventional glucocorticoid/immunosuppressive therapy.
PATIENTS AND METHODS
Patients and treatment. We reviewed the clinical records of all patients with adult-onset IgAV treated with RTX at 9 different vasculitis centers in Europe. The diagnosis of IgAV was based on the American College of Rheumatology 1990 criteria for the classification of Henoch-Sch€ onlein purpura (10) and the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides (1). All patients had to have a biopsy-proven diagnosis of IgAV. Patients were included if 1) their age at IgAV diagnosis was >18 years; 2) they had severe involvement of at least 1 organ (including biopsy-proven IgAV-related nephritis class 3-4 [2] ; gastrointestinal involvement with hemorrhage, ischemia, perforation, and/or abdominal pain unresponsive to common analgesics and lasting for >24 hours; pulmonary hemorrhage, episcleritis, cardiac and central nervous system involvement); 3) other systemic autoimmune or neoplastic diseases were excluded; and 4) RTX was given for the treatment of relapsing or refractory disease or because there were contraindications to the use of standard-dose glucocorticoids and/or conventional immunosuppressants.
Allowed RTX schedules included 375 mg/m 2 /week for 4 consecutive weeks or two 1,000 mg doses given 2 weeks apart; RTX could be given alone or in addition to other immunosuppressive therapies. Glucocorticoids and other immunosuppressants were tapered or withdrawn according to local practice. RTX was obtained by local hospital pharmacies for off-label use; all patients signed an informed consent. The study was performed in accordance with the Declaration of Helsinki and received ethical approval by the University of Parma Institutional Review Board.
Data collection and disease activity assessment. We retrieved data regarding patient demographics, clinical manifestations, disease duration, and treatments prior to RTX therapy and during post-RTX treatment follow-up, and reviewed all the pathology reports of diagnostic biopsies. With regard to posttreatment follow-up, we collected clinical and serologic data at specific time points (months 1, 6, 12, and last follow-up visit). Estimated glomerular filtration rate (GFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Information regarding any types of adverse events (AEs) was also collected; AEs were graded using the Common Terminology Criteria for Adverse Events version 4.0 (11). Disease activity was evaluated using the Birmingham Vasculitis Activity Score (BVAS), version 3 (12) . This score refers to new or worsening symptoms due to active vasculitis, with higher scores indicating more active disease. Remission was defined as a BVAS of 0, or as a BVAS of ≤5 if all scores were due to persistent hematuria or proteinuria in the presence of stable or improving renal function. Relapses were defined as an increase in disease activity requiring the reinstitution of glucocorticoids or other immunosuppressants, or as a significant increase in glucocorticoid dose (>50% for prednisone doses ≥15 mg/day or >100% for doses ≤12.5 mg/day). Disease was defined as refractory in case of lack of response to standard-dose glucocorticoids, either alone or combined with other immunosuppressive therapies.
Tissue biopsies. Renal biopsy findings compatible with a diagnosis of IgAV-related nephritis were classified as follows according to Pillebout et al (2) : class 1 = "mesangiopathic" glomerulonephritis; class 2 = focal and segmental glomerulonephritis (segmental endocapillary and/or extracapillary proliferation involving <50% of the glomeruli); class 3 = diffuse and severe endocapillary proliferative glomerulonephritis; class 4 = endocapillary and extracapillary glomerulonephritis; class 5 = global glomerular sclerosis involving >90% of the glomeruli. In order to investigate which inflammatory cell types are more abundant in the affected organs of patients with IgAV, we performed immunohistochemical analyses of 3 renal biopsy samples and 3 skin biopsy samples from patients included in this study. In addition to routine stainings (e.g., hematoxylin and eosin, periodic acid-Schiff) and immunofluorescence (to detect immunoglobulin and complement fraction deposition), we performed immunohistochemistry using monoclonal antibodies directed to the B cell marker CD20, the T cell marker CD3, and the macrophage marker CD163.
Statistical analysis. Continuous variables are expressed as the median and interquartile range (IQR), while categorical variables are expressed as the number (%). Variations in continuous variables between 2 time points were assessed using the Wilcoxon test. Variations in continuous variables across different time points (baseline, month 1, month 6, month 12, last followup visit) were assessed using Friedman's test. P values were corrected using Dunn's multiple comparison test. Corrected P values less than 0.05 were considered significant. Statistical analysis was performed using GraphPad Prism software, version 5.
RESULTS
Twenty-two patients were included in this study. Six of these patients were described in previous reports (8, 9) ; the data presented herein regarding these 6 patients are based on a longer follow-up period than that originally reported. Of the 22 patients, 12 were men; their median age at diagnosis was 37.5 years (IQR 22.8-49.8 years). At diagnosis, the most frequent clinical manifestation was purpura (in 21 patients [95.5%]); it predominantly affected the lower limbs and was necrotic or bullous in 6 cases (27.3%). Gastrointestinal involvement was found in 18 patients (81.8%); all experienced abdominal pain, and 7 (39%) experienced gastrointestinal hemorrhage. Twenty 110 MARITATI ET AL patients (90.9%) had kidney involvement. The median estimated GFR was 76 ml/minute/1.73 m 2 (IQR 65-104), and the median proteinuria was 1,900 mg/24 hours (IQR 580-3,275) ( Table 1) . One patient was dialysis-dependent at diagnosis but became dialysis-free after initial therapy (before RTX treatment). Fifteen patients (68.2%) underwent kidney biopsy, which confirmed IgAV in all cases. A diffuse endocapillary and/or extracapillary IgAV glomerulonephritis (classes 3-4) was observed in 9 of these 15 patients (60%). At diagnosis, disease activity assessment showed a median BVAS of 16.5 (IQR 13.0-23.8) ( Table 1) .
Sixteen patients (73%) had received other treatments prior to RTX; all of them had received glucocorticoids, either alone or combined with cyclophosphamide, azathioprine, mycophenolate mofetil, or other drugs (Table 1) . These 16 patients received RTX (only 1 as monotherapy) for refractory or relapsing disease. The remaining 6 patients received RTX as first-line therapy (5 as monotherapy and 1 together with low-dose glucocorticoids) because they had contraindications to standarddose glucocorticoids or other immunosuppressive agents. Overall, 16 patients received RTX as add-on therapy and 6 as monotherapy.
At RTX initiation, 18 patients (81.8%) had skin manifestations, 15 (68.2%) had gastrointestinal involvement, 18 (81.8%) had kidney involvement, and 16 (72.7%) had arthritis or arthralgia. The median BVAS was 15.0 (IQR 9.5-19.8), the median estimated GFR was 82 ml/ minute/1.73 m 2 (IQR 65-101), and the median proteinuria was 1,700 mg/24 hours (IQR 750-2,375) ( Table 2) .
One month after RTX treatment, 10 patients (45.5%) had achieved remission, and the BVAS had decreased significantly (median BVAS of 6 at month 1 versus 15 at baseline; P = 0.0005) (Figure 1 ). At month 6, 16 patients (72.7%) had disease in remission and 6 (27.3%) had active disease (3 because of persisting disease and 3 because of relapse after remission) ( Table 2) ; as compared with baseline, the BVAS and prednisone dose decreased (P = 0.0008 and P = 0.03, respectively). At month 12, 16 patients (72.7%) had disease in remission and 6 (27.3%) had active disease (persistent disease in 5 and disease relapse in 1); reductions from baseline were observed for BVAS (P = 0.0005), proteinuria (P = 0.001), C-reactive protein (CRP) level (P = 0.0007), and prednisone dose (P = 0.01) (Figure 1) . Thus, during the first 12 months after RTX treatment, remission was achieved by 20 patients (cumulative incidence of remission 90.9%), of whom 4 had relapse of disease. After remission, no patient received RTX as maintenance therapy. Of the 7 patients who were taking immunosuppressants at the time of RTX treatment, 3 stopped taking them (Table 2) . Eight patients were taking angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) at the time of RTX treatment; 4 stopped taking them during the first 12 months after RTX treatment (Table 2) but resumed taking them afterward, usually for hypertension, persistent proteinuria, or nonspecific nephroprotection.
We analyzed the outcomes at months 6 and 12 of the 6 patients who received RTX alone and compared them with those of the 16 patients who received RTX and glucocorticoids/immunosuppressants; no significant differences emerged (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40339/abstract). No differences in terms of remission and relapse rates were found between patients treated with either of the 2 different RTX regimens and between patients who received RTX as first-line therapy and those who received RTX for refractory/relapsing disease (data not shown). * Except where indicated otherwise, values are the number (%). RTX = rituximab; BVAS = Birmingham Vasculitis Activity Score; IQR = interquartile range; GFR = glomerular filtration rate; ACE = angiotensin-converting enzyme; ARBs = angiotensin receptor blockers. † Calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. ‡ At baseline, 4 patients were taking azathioprine, 1 was taking mycophenolate mofetil, 1 was taking sulfasalazine, and 1 was taking leflunomide. At month 1, 2 patients had stopped taking azathioprine. At month 6, an additional patient had stopped taking azathioprine. , and proteinuria throughout the study period. Significant reductions in BVAS (P < 0.0001), CRP level (P = 0.0005), prednisone dose (P < 0.0001), and 24-hour proteinuria (P < 0.0001) were observed after rituximab (RTX) therapy. No significant change of estimated GFR was found (P = 0.59). These variations were calculated using Friedman's test and corrected using Dunn's multiple comparison test. Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers. t0 = time of RTX therapy; t1 = month 1; t6 = month 6; t12 = month 12; last fu = last follow-up visit.
MARITATI ET AL
The median duration of follow-up from the start of RTX treatment was 24 months (IQR 18-48 months). At the last follow-up visit, 18 patients had disease in remission, 3 had active disease, and 1 was deceased (month 60 after RTX treatment). Of the patients with disease in remission, 3 were taking low-dose prednisone (2.5-5 mg/day), and 2 were taking low-dose prednisone and immunosuppressants. Reductions from RTX initiation through the last follow-up visit were observed for the BVAS (P < 0.0001), 24-hour proteinuria (P < 0.0001), CRP level (P = 0.0005), and prednisone dose (P < 0.0001) (Figure 1 ). Estimated GFR did not change significantly (median 77 ml/minute/ 1.73 m 2 at last follow-up visit versus 82 ml/minute/1.73 m 2 at baseline). At the last follow-up visit, 1 patient had developed ESRD requiring hemodialysis (month 13 after RTX treatment), 1 had stage 4 CKD, and 4 had proteinuria >1 gm/24 hours; 8 patients were taking ACE inhibitors or ARBs. Microhematuria persisted in 8 patients.
When considering the entire follow-up period, we recorded relapses in 7 of the 20 patients (35%) who had achieved remission. Relapses occurred a median of 12 months (IQR 6.5-15 months) after RTX treatment; they involved the kidney in 4 patients, the gastrointestinal tract in 1 patient, and the skin in 2 patients. Of the 4 patients with relapses involving the kidney, 3 were retreated with RTX and all achieved remission; only 1 received ACE inhibitors and developed ESRD. The 2 patients with relapses involving skin were successfully treated with either sulfasalazine (n = 1) or low-dose glucocorticoids (n = 1); the patient with a relapse involving the gastrointestinal tract also responded to resumption of low-dose glucocorticoids.
Circulating CD19+ B cell levels were not systematically tested and were only available for 11 patients, all of whom achieved B cell depletion (<0.01 9 10 9 cells/liter) after RTX treatment. Given the paucity of data, we could not establish any association between B cell return and relapse.
RTX therapy was generally well tolerated. Two patients experienced infusion reactions; 1 developed bullous urticaria (grade 3) that responded to oral steroids, while 1 developed mild and self-limited dyspnea (grade 2). In the first patient, the reaction precluded subsequent drug infusions. One patient died because of advanced liver cirrhosis (of undetermined etiology) and pneumonia (month 60 after RTX treatment), but this fatal event was probably unrelated to RTX given the long period of time elapsed since RTX therapy.
DISCUSSION
Adult-onset IgAV is a rare, often severe, small-vessel vasculitis; if left untreated, it usually has an adverse prognosis (2) . Current treatments, including high-dose glucocorticoids and cyclophosphamide, are only partially effective and their toxicity may be high (3, 4) . Our results identify RTX as an effective therapeutic option for adultonset IgAV. In our study, RTX was given for refractory/relapsing disease or as first-line therapy when conventional immunosuppressive agents were contraindicated. The remission rate after RTX treatment was 91%, with most patients achieving remission within 6 months of therapy. Remission was defined based on the BVAS, a widely used score for disease activity assessment in systemic vasculitides. However, other parameters such as CRP level and prednisone dose also declined after RTX treatment. Renal outcomes were good; although estimated GFR remained stable, the reduction in proteinuria was marked (~5-fold at end of follow-up versus baseline). Only 1 patient developed ESRD and 1 developed stage 4 CKD. Interestingly, the outcomes of patients treated with RTX monotherapy appeared to be similar to those of patients receiving combination therapies.
Relapses were common (relapse rate 35%) after RTX-induced remission; their clinical presentation was variable, and in severe cases retreatment with RTX proved effective. Overall, RTX was well tolerated; no major treatment-related AEs were recorded.
The potential mechanisms of action of RTX in IgAV are only a subject of speculation. As is the case in IgA nephropathy (13) , in IgAV immune complexes containing galactose-deficient IgA1 are thought to accumulate in target organs and initiate tissue damage. We could measure neither serum galactose-deficient IgA1 nor galactose-deficient IgA1-containing immune complexes; total serum IgA levels, available in 17 of 22 patients, showed a slight, progressive reduction after RTX treatment (P = 0.03) (see Supplementary Figure 1 , http://onlinelibrary. wiley.com/doi/10.1002/art.40339/abstract). However, the slow kinetics and the minor degree of IgA reduction did not seem to mirror the clinical activity of RTX. We also performed immunohistochemistry on renal and skin biopsy samples from IgAV patients (see Supplementary  Figure 2 , http://onlinelibrary.wiley.com/doi/10.1002/art. 40339/abstract) to investigate which cell types infiltrate target tissues; in all cases, CD20+ B cells were either absent or scarce, while most infiltrating cells were CD3+ T cells or CD163+ macrophages. Thus, although we cannot exclude the possibility that RTX in IgAV reduces the expansion of IgA-producing plasma cells or depletes tissue-infiltrating B cells, its therapeutic efficacy most likely results from the impairment of other B cell functions such as antigen presentation and T cell costimulation, as already postulated for ANCA-associated vasculitis and other autoimmune conditions (6) . RTX has recently been investigated in a randomized trial of patients with IgA nephropathy. In this trial, which enrolled patients at high risk of progression (persistent proteinuria >1 gm/day despite ACE inhibitors or ARBs), RTX failed to reduce proteinuria at 12 months; serum levels of galactose-deficient IgA1 or antibodies against galactose-deficient IgA1 were also unaffected (14) . The apparent contrast between our positive findings and the lack of efficacy of RTX in the IgA nephropathy trial could be due to several reasons. The chronic and advanced stage of IgA nephropathy of the patients enrolled in the trial may have impaired their response to RTX (14) . Additionally, it must be acknowledged that IgAV and IgA nephropathy are clinically distinct, with IgAV being certainly more "inflammatory" (15) . Their genetic associations are also different; although they are both associated with HLA class II variants, other associations with polymorphisms of genes involved in innate immune responses (e.g., ITGAM, CARD9) were only demonstrated for IgA nephropathy (13, 15) .
Our study has limitations, mainly related to its retrospective nature and the small sample size. Also, we cannot exclude the possibility that concomitant treatments such as other immunosuppressants, ACE inhibitors, or ARBs, although limited to a minority of patients, influenced patients' responses. Nevertheless, this study represents the largest reported experience on the use of RTX in adult-onset IgAV. We observed that RTX effectively induced disease remission, allowed glucocorticoid tapering, and was well tolerated. Larger, controlled studies are warranted to clarify its role in the management of this rare condition.
